Computational drug design based on artificial intelligence is an emerging research area. At the time of writing this paper, the world suffers from an outbreak of the coronavirus SARS-CoV-2. A promising way to stop the virus replication is via protease inhibition. We propose an evolutionary multi-objective algorithm (EMOA) to design potential protease inhibitors for SARS-CoV-2's main protease. Based on the SELFIES representation the EMOA maximizes the binding of candidate ligands to the protein using the docking tool QuickVina 2, while at the same time taking into account further objectives like drug-likeliness or the fulfillment of filter constraints. The experimental part analyzes the evolutionary process and discusses the inhibitor candidates.
@article{arxiv.2005.02666,
title = {Evolutionary Multi-Objective Design of SARS-CoV-2 Protease Inhibitor Candidates},
author = {Tim Cofala and Lars Elend and Philip Mirbach and Jonas Prellberg and Thomas Teusch and Oliver Kramer},
journal= {arXiv preprint arXiv:2005.02666},
year = {2020}
}